Research programme: human monoclonal antibodies - Centocor/Medarex
Alternative Names: HuMaBs - Centocor/MedarexLatest Information Update: 04 Nov 2017
At a glance
- Originator Centocor
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA (Parenteral)
- 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb